Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:CNTB NASDAQ:FBRX NASDAQ:NGNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$20.86+1.9%$20.55$89.95▼$99.05$604.63M0.9553,591 shs659,521 shsCNTBConnect Biopharma$2.38+1.7%$2.28$1.23▼$3.82$149.85M-0.23665,244 shs380,425 shsFBRXForte Biosciences$48.86+8.6%$23.24$9.10▼$50.00$678.47M2.85896,642 shs595,739 shsNGNENeurogene$37.31+2.2%$31.32$15.93▼$43.66$589.57M1.68293,275 shs473,344 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+1.86%-0.43%+23.65%-8.71%+131.78%CNTBConnect Biopharma0.00%-5.18%+19.00%-15.30%+46.91%FBRXForte Biosciences0.00%+11.25%+173.73%+44.04%+404.75%NGNENeurogene0.00%-5.85%+18.33%+33.97%+65.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$20.86+1.9%$20.55$89.95▼$99.05$604.63M0.9553,591 shs659,521 shsCNTBConnect Biopharma$2.38+1.7%$2.28$1.23▼$3.82$149.85M-0.23665,244 shs380,425 shsFBRXForte Biosciences$48.86+8.6%$23.24$9.10▼$50.00$678.47M2.85896,642 shs595,739 shsNGNENeurogene$37.31+2.2%$31.32$15.93▼$43.66$589.57M1.68293,275 shs473,344 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+1.86%-0.43%+23.65%-8.71%+131.78%CNTBConnect Biopharma0.00%-5.18%+19.00%-15.30%+46.91%FBRXForte Biosciences0.00%+11.25%+173.73%+44.04%+404.75%NGNENeurogene0.00%-5.85%+18.33%+33.97%+65.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ACNTBConnect Biopharma 2.89Moderate Buy$7.29206.12% UpsideFBRXForte Biosciences 2.50Moderate Buy$67.0037.13% UpsideNGNENeurogene 3.00Buy$84.83127.37% UpsideCurrent Analyst Ratings BreakdownLatest CNTB, NGNE, FBRX, and AVTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026CNTBConnect Biopharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.007/8/2026FBRXForte Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/30/2026CNTBConnect Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/26/2026CNTBConnect Biopharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral ➝ Overweight$7.006/26/2026CNTBConnect Biopharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral ➝ Overweight$7.006/25/2026CNTBConnect Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.006/18/2026CNTBConnect Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.006/9/2026NGNENeurogene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.006/3/2026NGNENeurogene UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$70.006/3/2026NGNENeurogene Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$70.006/3/2026NGNENeurogene Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$70.00(Data available from 7/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ACNTBConnect Biopharma$233K643.15N/AN/A$0.75 per share3.17FBRXForte BiosciencesN/AN/AN/AN/A$4.71 per shareN/ANGNENeurogeneN/AN/AN/AN/A$17.10 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/ACNTBConnect Biopharma-$55.48M-$1.15N/AN/AN/AN/A-122.29%-97.07%8/12/2026 (Estimated)FBRXForte Biosciences-$69.38M-$4.64N/AN/AN/AN/A-106.17%-85.50%8/13/2026 (Estimated)NGNENeurogene-$90.35M-$4.55N/AN/AN/AN/A-37.88%-34.70%8/10/2026 (Estimated)Latest CNTB, NGNE, FBRX, and AVTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026FBRXForte Biosciences-$1.03N/AN/AN/AN/AN/A8/12/2026Q2 2026CNTBConnect Biopharma-$0.32N/AN/AN/A$0.11 millionN/A8/10/2026Q2 2026NGNENeurogene-$1.40N/AN/AN/AN/AN/A5/12/2026Q1 2026CNTBConnect Biopharma-$0.29-$0.34-$0.05-$0.34N/A$0.02 million5/12/2026Q1 2026NGNENeurogene-$1.2963-$1.39-$0.0938-$1.39N/AN/A5/11/2026Q1 2026FBRXForte Biosciences-$1.16-$1.24-$0.08-$1.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78CNTBConnect Biopharma0.013.233.23FBRXForte BiosciencesN/A2.752.75NGNENeurogeneN/A13.0813.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ACNTBConnect Biopharma58.72%FBRXForte Biosciences77.63%NGNENeurogene52.37%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%CNTBConnect Biopharma22.60%FBRXForte Biosciences4.40%NGNENeurogene11.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableCNTBConnect Biopharma11062.96 million48.73 millionOptionableFBRXForte Biosciences513.89 million13.28 millionOptionableNGNENeurogene9015.80 million13.96 millionOptionableCNTB, NGNE, FBRX, and AVTE HeadlinesRecent News About These CompaniesNeurogene (NASDAQ:NGNE) Shares Gap Down - Here's WhyJuly 17 at 10:59 AM | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Buy" by BrokeragesJuly 13, 2026 | marketbeat.comNeurogene (NGNE) Receives a Buy from LifeSci CapitalJuly 12, 2026 | theglobeandmail.comNeurogene (NASDAQ:NGNE) CFO Christine Mikail Cvijic Sells 600 SharesJuly 8, 2026 | insidertrades.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | businesswire.comNeurogene announces pricing of $125 million public offeringJuly 3, 2026 | thepharmaletter.comTInsider Selling: Neurogene (NASDAQ:NGNE) CFO Sells $25,170.34 in StockJuly 3, 2026 | insidertrades.comNeurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline DataJuly 2, 2026 | seekingalpha.comNeurogene bolsters cash runway with equity offeringJuly 2, 2026 | tipranks.comNeurogene Inc. Announces Pricing of $125 Million Public OfferingJuly 1, 2026 | finance.yahoo.comNeurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome - SlideshowJuly 1, 2026 | seekingalpha.comNeurogene Inc. Announces Proposed Public OfferingJune 30, 2026 | finance.yahoo.comNeurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome TranscriptJune 29, 2026 | seekingalpha.comNeurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett SyndromeJune 29, 2026 | finance.yahoo.comNeurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett SyndromeJune 8, 2026 | finance.yahoo.comNeurogene Announces Successful Completion of Dosing in Emboldenâ„¢ Registrational Trial of NGN-401 for Rett SyndromeJune 8, 2026 | businesswire.comNeurogene Stockholders Vote on Directors and Executive PayJune 4, 2026 | tipranks.comNeurogene Reports First Quarter 2026 Financial Results and Highlights Recent UpdatesMay 12, 2026 | businesswire.comInsider Selling: Neurogene (NASDAQ:NGNE) CFO Sells 9,600 Shares of StockMay 9, 2026 | insidertrades.comWe Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business GrowthMay 5, 2026 | finance.yahoo.comNeurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene TherapyApril 28, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNTB, NGNE, FBRX, and AVTE Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$20.86 +0.38 (+1.86%) As of 07/17/2026Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Connect Biopharma NASDAQ:CNTB$2.38 +0.04 (+1.71%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$2.38 0.00 (0.00%) As of 07/17/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Forte Biosciences NASDAQ:FBRX$48.86 +3.87 (+8.60%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$48.78 -0.08 (-0.16%) As of 07/17/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Neurogene NASDAQ:NGNE$37.31 +0.81 (+2.22%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$37.38 +0.07 (+0.20%) As of 07/17/2026 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/13- 07/17 The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Wall Street Suddenly Sees SpaceX as an AI Company TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth Why Intuitive Surgical’s Strong Quarter Still Spooked Investors Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
